

February 16, 2011
AnGes MG, Inc.

AnGes MG's Founder Receives the "Japan Venture Awards 2011"
— Awarded for excellency in the founding of venture businesses and management —

To promote the creation of new business and the rise of entrepreneurs who will become tomorrow's leaders of Japan, the "Venture Spirits 2011 in Tokyo", a seminar-like event, was held today under the theme of encouragement and promotion of business startups. At this event, Ryuichi Morishita, the founder and board member of AnGes MG, Inc. and Professor of Osaka University, won the "Chairman of the Organization for Small and Medium Enterprises and Regional Innovation Award".

The Japan Venture Awards are given to entrepreneurs who have high aspirations to operate excellent businesses in terms of social value, advanced proprietary, innovation, regionality, internationality and technology, and also the challenge of facing risks without fear. The awards are also intended to widely introduce founders supporting local economies and employment opportunities as well as venture business managers leading the Japanese economy as role models, thereby boosting business momentum and promoting the nation's entrepreneurship. It is hosted by the Organization for Small and Medium Enterprises and Regional Innovation, and sponsored by the Small and Medium Enterprise Agency of the Ministry of Economy, Trade and Industry.

AnGes MG is a venture company that excels in the establishment of basic technologies and R&D of gene medicine, especially gene therapy products and nucleic acid medicines, which are Japan originated innovative new products, and aims for the global market deployment of such products. AnGes MG has already market-launched a therapeutic agent for mucopolysaccharidosis, a hereditary and intractable disease. AnGes MG has been promoting, in Japan, the United States, and Europe, the development of new drugs effective against various intractable diseases, such as arteriosclerosis obliterans, atopic dermatitis, vascular restenosis, malignant melanoma, and skin ulcer, for which new therapeutic drugs are highly awaited.

This award is the validation of AnGes MG's business foundation and comprehensive activities including R&D of innovative drugs for the treatment of intractable diseases, as well as the company's standing as a pioneering bioventure in Japan, possessing world-class intellectual property, basic technologies and drug development expertise; such corporate properties are highly recognized as an ideal business model for future entrepreneurs.

Meanwhile, this event will have no effect on AnGes MG's business performance for the current fiscal year.